Ardelyx Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ardelyx (Fremont, CA): 2 reconciled FDA prescription therapies, $243.8M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterFremont, CA
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2042-01-01
2024 CMS Total Public Spend$243.8M
2024 Medicare Part D Spend$189.9M
2024 Medicaid Spend$53.9M
California HCAI SB 17 Filings2 WAC filings (max 20.2% 2-yr change)